CLINICAL_TRIALS
trial_result
· 2018-04-17
Clinical Trial Update: Nintedanib Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF) [Phase 3]
Summary
Phase 3 trial results comparing nintedanib taken twice daily to placebo in idiopathic pulmonary fibrosis were posted in 2018.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Boehringer Ingelheim | Conditions: Idiopathic Pulmonary Fibrosis | Phase 3 | Status: COMPLETED | Results posted: 2018-04-17